Zebrafish studies of exocrine pancreatic precursors

斑马鱼外分泌胰腺前体的研究

基本信息

  • 批准号:
    6885382
  • 负责人:
  • 金额:
    $ 16.35万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-04-15 至 2006-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The identity and location of epithelial precursor cells in exocrine pancreas remain unknown. Further characterization of this precursor population would represent a significant advance in our understanding of pancreatic development, pancreatic regeneration and pancreatic cancer. While studies in mice and other rodents have provided important initial insights, these species have significant limitations related to many aspects of genetic manipulation. The zebrafish (Danio rerio) has recently emerged as a central model organism in the study of vertebrate development. The increasingly widespread use of the zebrafish reflects significant advantages with respect to embryo access, simplified techniques for gain-of-function and loss-of-function analysis, and forward genetic capabilities. Recent studies have suggested that many aspects of pancreas development in the zebrafish are conserved with respect to other vertebrate species. Based on a recent NIDDK program announcement requesting proposals for innovative and exploratory research involving pancreatic stem cells and/or novel animal models (PA-01-129), we have embarked on initial studies of zebrafish exocrine pancreas development. The long-term goal of this research program is to identify and rigorously characterize exocrine pancreatic precursors in zebrafish pancreas, ultimately allowing use of this organism as a novel model system for study of human pancreatic disease. Our preliminary studies have involved cloning and characterization of the zebrafish orthologue for PTF1a-p48, a basic helix-loop-helix transcription factor required for normal pancreas development in the mouse. Initial gene expression and p48 morpholino knock-down studies have suggested fundamental and informative differences between zebrafish and mouse with respect to the relationship between endocrine and exocrine precursor pools. Based on these findings, we propose that identification and characterization of p48-positive precursors in zebrafish pancreas will allow investigation of conserved regulatory mechanisms not discernable in the mouse, and that novel regulators of pancreatic development will be identified among genes differentially expressed in wild-type vs. p48 morphant embryos. To test these hypotheses, the following Specific Aims will be pursued: First, to rigorously determine the identity, location, and gene expression profiles of p48-positive precursor cells in developing zebrafish pancreas. Second, to determine the contribution of p48-positive precursors to endocrine and exocrine lineages; and finally, to identify novel p48 target genes responsible for mediating the effects of p48 on early pancreas development. It is anticipated that these studies will provide important new insights regarding regulation of exocrine pancreatic precursor cells, and further establish the zebrafish as a novel model system for the study of epithelial differentiation in exocrine pancreas.
描述(由申请人提供):外分泌胰腺中上皮前体细胞的身份和位置仍然未知。对这种前体人群的进一步表征将是我们对胰腺发育,胰腺再生和胰腺癌的理解的重大进步。尽管在小鼠和其他啮齿动物的研究中提供了重要的初始见解,但这些物种具有与遗传操纵许多方面有关的重大局限性。斑马鱼(Danio Rerio)最近在脊椎动物发育研究中成为一种中央模型生物。斑马鱼的越来越广泛使用反映了在胚胎接入,简化功能获得和功能丧失分析以及正向遗传能力方面的显着优势。最近的研究表明,斑马鱼中胰腺发育的许多方面都是相对于其他脊椎动物的保守的。基于最近的NIDDK计划公告,要求提出有关涉及胰腺干细胞和/或新型动物模型的创新和探索性研究的建议(PA-01-129),我们已经开始对斑马鱼外分泌胰腺发育的初步研究。该研究计划的长期目标是确定并严格地表征斑马鱼胰腺中的外分泌胰腺前体,最终允许使用该生物作为研究人胰腺疾病的新型模型系统。我们的初步研究涉及对PTF1A-P48的斑马鱼直系同源物的克隆和表征,PTF1A-P48是小鼠正常胰腺发育所需的基本螺旋 - 环螺旋转录因子。最初的基因表达和p48形态敲低的研究表明,斑马鱼和小鼠之间在内分泌和外分泌前体池之间的关系方面存在基本和信息性差异。基于这些发现,我们提出,斑马鱼胰腺中P48阳性前体的鉴定和表征将允许研究小鼠中无法识别的保守调节机制,并且在野生型Pe中在基因中鉴定出胰腺发育的新型调节剂,并且会在野外表达中鉴定出来。 vs. P48形态胚胎。为了检验这些假设,将追求以下特定目标:首先,严格确定斑马鱼胰腺中P48阳性前体细胞的身份,位置和基因表达谱。其次,确定p48阳性前体对内分泌和外分泌谱系的贡献;最后,确定新型的P48靶基因,负责介导p48对胰腺早期发育的影响。可以预料,这些研究将提供有关调节外分泌胰腺前体细胞的重要新见解,并进一步建立斑马鱼,作为研究外分泌胰腺上皮分化的新型模型系统。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Steven D Leach其他文献

Steven D Leach的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Steven D Leach', 18)}}的其他基金

Developing ATAC-array as a novel epigenetic biomarker to guide personalized therapy in pancreatic cancer
开发 ATAC 阵列作为新型表观遗传生物标志物来指导胰腺癌的个性化治疗
  • 批准号:
    10512502
  • 财政年份:
    2022
  • 资助金额:
    $ 16.35万
  • 项目类别:
Administrative supplement for Early Drug Development Opportunity Program (EDDOP)
早期药物开发机会计划 (EDDOP) 的行政补充
  • 批准号:
    10677500
  • 财政年份:
    2022
  • 资助金额:
    $ 16.35万
  • 项目类别:
P30 Administrative Supplement to Cancer Center Support Grant to Strengthen NCI-Supported Community Outreach Capacity through Community Health Educators of the National Outreach Network.
P30 癌症中心支持补助金的行政补充,旨在通过国家外展网络的社区健康教育者加强 NCI 支持的社区外展能力。
  • 批准号:
    10370916
  • 财政年份:
    2021
  • 资助金额:
    $ 16.35万
  • 项目类别:
Community-led Action Research in Oncology: Pandemic-appropriate Radiotherapy Innovations Evaluated for LMICs
社区主导的肿瘤学行动研究:针对中低收入国家评估适合流行病的放射治疗创新
  • 批准号:
    10380931
  • 财政年份:
    2021
  • 资助金额:
    $ 16.35万
  • 项目类别:
Comprehensive genetic dissection of druggable KRAS targets
可药物 KRAS 靶点的全面基因剖析
  • 批准号:
    9476973
  • 财政年份:
    2016
  • 资助金额:
    $ 16.35万
  • 项目类别:
Comprehensive genetic dissection of druggable KRAS targets
可药物 KRAS 靶点的全面基因剖析
  • 批准号:
    9922888
  • 财政年份:
    2016
  • 资助金额:
    $ 16.35万
  • 项目类别:
Comprehensive genetic dissection of druggable KRAS targets
可药物 KRAS 靶点的全面基因剖析
  • 批准号:
    9080884
  • 财政年份:
    2016
  • 资助金额:
    $ 16.35万
  • 项目类别:
Functional Evaluation of Human Pancreatic Cancer Genes in a Zebrafish System
斑马鱼系统中人类胰腺癌基因的功能评估
  • 批准号:
    8464656
  • 财政年份:
    2013
  • 资助金额:
    $ 16.35万
  • 项目类别:
High resolution and single cell analyses of PanIN initiation and progression
PanIN 起始和进展的高分辨率单细胞分析
  • 批准号:
    8248212
  • 财政年份:
    2011
  • 资助金额:
    $ 16.35万
  • 项目类别:
High resolution and single cell analyses of PanIN initiation and progression
PanIN 起始和进展的高分辨率单细胞分析
  • 批准号:
    8095001
  • 财政年份:
    2011
  • 资助金额:
    $ 16.35万
  • 项目类别:

相似国自然基金

维生素E-PEG修饰自组装反义核酸药物靶向MAPK14和BChE治疗神经炎症诱发阿尔兹海默症的应用基础研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
持续碱基配对竞争降低反义锁核酸药物脱靶毒性的研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
基于核糖核酸内切酶水解靶向嵌合分子技术的反义核酸的设计合成及活性研究
  • 批准号:
  • 批准年份:
    2021
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
基于反义核酸立体位阻上游开放阅读框探讨帕金森病常染色体隐性遗传致病基因翻译调控的研究
  • 批准号:
    82101505
  • 批准年份:
    2021
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
外显子跳跃式反义核酸武装的NK外泌体介导肿瘤免疫协同治疗
  • 批准号:
  • 批准年份:
    2020
  • 资助金额:
    24 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Molecular Mechanisms of Bladder Cancer Immunometabolism
膀胱癌免疫代谢的分子机制
  • 批准号:
    10584835
  • 财政年份:
    2023
  • 资助金额:
    $ 16.35万
  • 项目类别:
Modulation of Somatic Repeat Expansion as a Therapeutic Approach to Huntington's Disease
调节体细胞重复扩增作为亨廷顿病的治疗方法
  • 批准号:
    10678016
  • 财政年份:
    2023
  • 资助金额:
    $ 16.35万
  • 项目类别:
Programmable antivirals: Targeting viral RNA secondary structures with LNAs and small molecules
可编程抗病毒药物:利用 LNA 和小分子靶向病毒 RNA 二级结构
  • 批准号:
    10514269
  • 财政年份:
    2022
  • 资助金额:
    $ 16.35万
  • 项目类别:
Development of Advanced Oligonucleotides for Glioblastoma Therapeutics
用于胶质母细胞瘤治疗的先进寡核苷酸的开发
  • 批准号:
    10589879
  • 财政年份:
    2021
  • 资助金额:
    $ 16.35万
  • 项目类别:
Development of Advanced Oligonucleotides for Glioblastoma Therapeutics
用于胶质母细胞瘤治疗的先进寡核苷酸的开发
  • 批准号:
    10363662
  • 财政年份:
    2021
  • 资助金额:
    $ 16.35万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了